PMV Pharmaceuticals Announces Participation at the Goldman Sachs Annual Healthcare Conference
CRANBURY, N.J., June 03, 2021 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutants, today announced that David H. Mack, Ph.D., President & Chief Executive Officer, will present at the Goldman Sachs Annual Global Healthcare Conference on Wednesday, June 9, 2021. The company will also participate in one-on-one investor meetings at the conference.
Details on the presentation can be found below.
Goldman Sachs Annual Global Healthcare Conference
| Date: | Wednesday, June 9, 2021 |
| Time: | 5:30 PM ET |
| Webcast: | https://kvgo.com/gs-global-healthcare/pmv-pharmaceuticals-june-2021 |
A replay of the presentation will be available by visiting the “Events & Presentations” section of the PMV Pharmaceuticals website.
About PMV Pharma
PMV Pharma is a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutants. p53 mutations are found in approximately half of all cancers. The field of p53 biology was established by our co-founder Dr. Arnold Levine when he discovered the p53 protein in 1979. Bringing together leaders in the field to utilize over four decades of p53 biology, PMV Pharma combines unique biological understanding with pharmaceutical development focus. PMV Pharma is headquartered in Cranbury, New Jersey. For more information, please visit www.pmvpharma.com.
Contact
For Investors & Media:
Winston Kung
Chief Financial Officer
investors@pmvpharma.com
